球囊血管成形术与药物治疗颅内动脉狭窄:BASIS随机临床试验
BASIS试验在中国31个中心随机纳入501例症状性颅内动脉粥样硬化性狭窄(70%-99%狭窄)患者,比较亚最大球囊血管成形术联合强化药物治疗与单纯强化药物治疗。主要复合终点(30天内任何卒中或死亡,或30天至12个月责任动脉缺血性卒中或血运重建)发生率球囊组4.4% vs 药物组13.5%(HR 0.32,95%CI 0.16-0.63;P<.001)。球囊组30天内任何卒中或全因死亡3.2% vs 1.6%,症状性颅内出血1.2% vs 0.4%,手术并发症17.4%,动脉夹层14.5%。作者认为球囊血管成形术联合强化药物治疗可能为sICAS的有效治疗,但临床实践应考虑球囊术后30天内卒中或死亡风险。
要点
- 症状性颅内动脉粥样硬化性狭窄(70%-99%)患者,球囊血管成形术联合强化药物治疗较单纯强化药物治疗显著降低主要复合终点(4.4% vs 13.5%;HR 0.32,95%CI 0.16-0.63;P<.001)。
- 球囊组30天内任何卒中或全因死亡率为3.2%,药物组为1.6%。
- 30天至1年,球囊组责任动脉区域任何缺血性卒中率为0.4%,药物组为7.5%;责任动脉血运重建率分别为1.2%和8.3%。
- 球囊组症状性颅内出血发生率为1.2%,药物组为0.4%;球囊组手术并发症发生率为17.4%,动脉夹层发生率为14.5%。
适用人群与场景
- 年龄35至80岁,近期(入组前<90天)短暂性脑缺血发作或(14-90天)缺血性卒中,归因于主要颅内动脉70%至99%动脉粥样硬化性狭窄,且正在接受至少1种抗血栓药物和/或标准危险因素管理的患者。
诊断标准与关键阈值
- 症状性颅内动脉粥样硬化性狭窄定义为:入组前<90天的短暂性脑缺血发作或14-90天的缺血性卒中,归因于主要颅内动脉70%至99%动脉粥样硬化性狭窄。
处置流程与药物剂量
- 亚最大球囊血管成形术联合强化药物治疗(n=249)。
- 强化药物治疗(n=252):前90天双联抗血小板治疗,并控制危险因素。
研究设计与关键结果
- randomized, open-label, blinded end point clinical trial at 31 centers across China; 512 randomized, 501 confirmed eligible (mean age 58.0 years; 158 [31.5%] women) and completed the trial.
- 主要终点(30天内任何卒中或死亡,或球囊血管成形术后30天内,或30天至12个月责任动脉缺血性卒中或责任动脉血运重建)发生率:球囊组4.4% vs 药物组13.5%;HR 0.32(95%CI 0.16-0.63);P<.001。
- 30天内任何卒中或全因死亡率:球囊组3.2% vs 药物组1.6%。
- 30天至1年责任动脉区域任何缺血性卒中率:球囊组0.4% vs 药物组7.5%;责任动脉血运重建率:球囊组1.2% vs 药物组8.3%。
- 症状性颅内出血率:球囊组1.2% vs 药物组0.4%。
- 球囊组手术并发症发生率17.4%,动脉夹层发生率14.5%。
证据类型、等级与局限
- 证据类型:随机、开放标签、盲法终点临床试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,球囊血管成形术联合强化药物治疗可能为症状性颅内动脉粥样硬化性狭窄的有效治疗,但临床实践应考虑球囊血管成形术后30天内卒中或死亡的风险。
- 原文未据此给出其他推荐。
指南或共识出处
- BASIS随机临床试验(ClinicalTrials.gov Identifier: NCT03703635)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Previous randomized clinical trials did not demonstrate the superiority of endovascular stenting over aggressive medical management for patients with symptomatic intracranial atherosclerotic stenosis (sICAS). However, balloon angioplasty has not been investigated in a randomized clinical trial.
OBJECTIVE: To determine whether balloon angioplasty plus aggressive medical management is superior to aggressive medical management alone for patients with sICAS.
DESIGN, SETTING, AND PARTICIPANTS: A randomized, open-label, blinded end point clinical trial at 31 centers across China. Eligible patients aged 35 to 80 years with sICAS defined as recent transient ischemic attack (<90 days) or ischemic stroke (14-90 days) before enrollment attributed to a 70% to 99% atherosclerotic stenosis of a major intracranial artery receiving treatment with at least 1 antithrombotic drug and/or standard risk factor management were recruited between November 8, 2018, and April 2, 2022 (final follow-up: April 3, 2023).
INTERVENTIONS: Submaximal balloon angioplasty plus aggressive medical management (n = 249) or aggressive medical management alone (n = 252). Aggressive medical management included dual antiplatelet therapy for the first 90 days and risk factor control.
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of any stroke or death within 30 days after enrollment or after balloon angioplasty of the qualifying lesion or any ischemic stroke in the qualifying artery territory or revascularization of the qualifying artery after 30 days through 12 months after enrollment.
RESULTS: Among 512 randomized patients, 501 were confirmed eligible (mean age, 58.0 years; 158 [31.5%] women) and completed the trial. The incidence of the primary outcome was lower in the balloon angioplasty group than the medical management group (4.4% vs 13.5%; hazard ratio, 0.32 [95% CI, 0.16-0.63]; P < .001). The respective rates of any stroke or all-cause death within 30 days were 3.2% and 1.6%. Beyond 30 days through 1 year after enrollment, the rates of any ischemic stroke in the qualifying artery territory were 0.4% and 7.5%, respectively, and revascularization of the qualifying artery occurred in 1.2% and 8.3%, respectively. The rate of symptomatic intracranial hemorrhage in the balloon angioplasty and medical management groups was 1.2% and 0.4%, respectively. In the balloon angioplasty group, procedural complications occurred in 17.4% of patients and arterial dissection occurred in 14.5% of patients.
CONCLUSIONS AND RELEVANCE: In patients with sICAS, balloon angioplasty plus aggressive medical management, compared with aggressive medical management alone, statistically significantly lowered the risk of a composite outcome of any stroke or death within 30 days or an ischemic stroke or revascularization of the qualifying artery after 30 days through 12 months. The findings suggest that balloon angioplasty plus aggressive medical management may be an effective treatment for sICAS, although the risk of stroke or death within 30 days of balloon angioplasty should be considered in clinical practice.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03703635.
参考来源
- Sun X, Deng Y, Zhang Y, et al. Balloon Angioplasty vs Medical Management for Intracranial Artery Stenosis: The BASIS Randomized Clinical Trial. JAMA. 2024. PMID: 39235816. doi:10.1001/jama.2024.12829
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。